- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05564390
MyeloMATCH MSRP: um estudo de triagem para atribuir pessoas com câncer mieloide a um estudo de tratamento
Protocolo Mestre de Triagem e Reavaliação (MSRP) para os Ensaios Clínicos NCI MyeloMATCH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Medicamento: Cytarabine
- Medicamento: Gemtuzumab Ozogamicin
- Procedimento: Bone Marrow Biopsy
- Biológico: Epoetin Alfa
- Procedimento: Computed Tomography
- Procedimento: Echocardiography Test
- Procedimento: Multigated Acquisition Scan
- Procedimento: Biopsy Procedure
- Procedimento: Positron Emission Tomography
- Procedimento: Bone Marrow Aspiration
- Medicamento: Daunorubicin
- Medicamento: Daunorubicin Hydrochloride
- Medicamento: Busulfan
- Medicamento: Venetoclax
- Medicamento: Fludarabine
- Medicamento: Decitabine and Cedazuridine
- Medicamento: Placebo Administration
- Medicamento: Azacitidine
- Medicamento: Liposome-encapsulated Daunorubicin-Cytarabine
- Procedimento: Biospecimen Collection
- Medicamento: Enasidenib
- Biológico: Luspatercept
- Biológico: Emavusertib
- Medicamento: Gilteritinib
- Medicamento: Olutasidenib
- Outro: Best Practice
- Medicamento: Quizartinib
- Procedimento: Allogeneic Hematopoietic Stem Cell Transplantation
- Procedimento: Chest Radiography
- Medicamento: Melphalan
- Radiação: Total-Body Irradiation
- Procedimento: Mutation Carrier Screening
Descrição detalhada
PRIMARY OBJECTIVES:
I. Screening and Reassessment (MSRP): To evaluate the feasibility of MATCHBox receiving and organizing all data needed for assignment to a myeloMATCH clinical trial or Tier Advancement Pathway (TAP) within 72 hours of MDNet receipt of all required specimens for initial therapy and within 10 days for subsequent therapy.
II. Tier Advancement Pathway (TAP): To enable participants who are not matched to an investigational myeloMATCH treatment substudy to receive standard of care (SOC) while remaining on the MSRP to maintain access to later tiers of treatment substudies.
SECONDARY OBJECTIVES:
I. Screening and Reassessment (MSRP):
Ia. To describe the time to generation of all data required for treatment substudy (or TAP) assignment, time to treatment substudy (or TAP) assignment, percent assigned to a myeloMATCH treatment substudy, and the percent of screened participants who register to a myeloMATCH investigational treatment substudy or are assigned to TAP:
Iai. Separately within each tier of myeloMATCH treatment substudy and analogous TAP assignment; Ibi. Separately within each clinical basket of myeloMATCH treatment substudies; Ici. Over time, across and within the categories above.
II. Tier Advancement Pathway (TAP):
IIa. To evaluate participants for assignment to higher tier treatment substudies within myeloMATCH; IIb. To describe, within tier- and basket- levels of TAP, measurable residual disease (MRD) rates and clonal evolution; IIc. To describe, within tier- and basket- levels of TAP, remission status and overall survival of participants who receive standard of care therapy; IId. To obtain MDNet specimens for translational medicine and biobanking.
OUTLINE:
REGISTRATION: Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP.
TAP: Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment.
TREATMENT: Patients are assigned to a specific treatment substudy.
MM1YA-CTG01: Younger patients (age 18-59 years) with intermediate risk acute myeloid leukemia (AML) are randomized to 1 of 3 arms.
ARM I: Patients receive daunorubicin intravenously (IV) on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax orally (PO) once daily (QD) on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening.
ARM II: Patients receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.
ARM III: Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.
MM1YA-S01: Younger patients (age 18-59 years) with high-risk AML are randomized to 1 of 5 arms.
ARM I: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM II: Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM III: Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM IV: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM V: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
MM2YA-EA01: Younger patients (age 18-59 years) with AML or secondary AML who have completed a tier 1 MyeloMATCH treatment study with complete remission (CR) or CR with partial hematologic recovery (CRh) and have detectable minimal residual disease (MRD) (> 0.1%) are randomized to 1 of 4 arms.
ARM A: Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM B: Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM C: Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM D: Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
MM1OA-EA02: Patients are randomized to 1 of 3 regimens.
REGIMEN 1:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
REGIMEN 2:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
REGIMEN 3:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
MM1MDS-A01: Patients are randomized to 1 of 2 regimens.
REGIMEN 1: Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 1. Patients who experience CR, PR, or stable disease (SD) any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
REGIMEN 2: Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
MM1OA-S03: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
ARM 2: Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
MM1YA-A04: Patients are randomized to 1 of 2 regimens.
REGIMEN 1: Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.
REGIMEN 2: Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.
MM3TCT-A03: Patients with matched donors are randomized to conditioning 1A or 1B. Patients with haploidentical or mismatched unrelated donors are randomized to conditioning 2A or 2B.
CONDITIONING 1A: Patients receive venetoclax PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or twice daily (BID) on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 1B: Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 2A: Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 2B: Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: All patients without evidence of relapse at day +100 are re-randomized to maintenance I or II.
MAINTENANCE I: Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE II: Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.
Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo positron emission tomography (PET) scan and/or computed tomography (CT) scan throughout the study.
MM1OA-MDS-A05: Patients are assigned to 1 of 3 cohorts.
COHORT A: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
ARM 2: Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
COHORT B: Patients are randomized to 1 of 2 arms.
ARM 3: Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
ARM 4: Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
COHORT C: Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
MM1MDS-CTG02: This is a dose-escalation study of luspatercept in combination, dependent upon arms assignments, with fixed dose epoetin alfa or emavusertib. Patients are randomized to 1 of 3 arms.
ARM 1: Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
ARM 2: Patients receive luspatercept SC on day 1 and epoetin alfa SC once weekly (QW) for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
ARM 3: Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
MM1YA-EA05: Patients are randomized to 1 of 2 arms.
ARM A:
INDUCTION: Patients receive cytarabine IV, over 24 hours, on days 1-7, daunorubicin IV on days 1-3, and quizartinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspiration/biopsy. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts may repeat induction as described starting on day 28-45. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts proceed to consolidation, following count recovery, by 30 days post-confirmation of CR/CRi. Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts repeat the bone marrow aspiration/biopsy 1 week later and then either repeat induction or proceed to consolidation, based on results. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts proceed to consolidation.
CONSOLIDATION: Patients receive cytarabine IV, over 1-3 hours, every 12 hours on days 1, 3 and 5 and quizartinib PO QD on days 6-19 in the absence of disease progression or unacceptable toxicity.
ARM B:
CYCLE 1: Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9, venetoclax PO QD on days 1-28, and quizartinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity and based on bone marrow findings. Patients undergo bone marrow aspiration/biopsy on day 14 of cycle 1. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts continue treatment as described through day 28 of cycle 1 and then proceed to cycle 2 without interruption or delay, as long as repeat bone marrow aspiration/biopsy on day 28 of cycle 1 is consistent with persistent blasts > 5%. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28) and then proceed to cycle 2 of treatment as described following count recovery. Patients without count recovery by day 42 undergo repeat bone marrow aspiration/biopsy. Patients with count recovery by day 42 proceed to cycle 2 (by day 50). For patients without count recovery by day 50 whose repeat bone marrow aspiration/biopsy shows no blasts, initiation of cycle 2 will be discussed with the study chairs. Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib, undergo repeat bone marrow aspiration/biopsy 1 week later, and proceed based on repeat biopsy results as described. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28) and then proceed to cycle 2 of treatment as described following count recovery. Patients without count recovery by day 42 undergo repeat bone marrow aspiration/biopsy. Patients with count recovery by day 42 proceed to cycle 2 (by day 50). For patients without count recovery by day 50 whose repeat bone marrow aspiration/biopsy shows no blasts, initiation of cycle 2 will be discussed with the study chairs.
CYCLE 2: Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9, venetoclax PO QD on days 1-28, and quizartinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity and based on bone marrow findings. Patients who do not achieve response after completion of cycle 1 undergo bone marrow aspiration/biopsy on day 14 of cycle 2. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts continue venetoclax and quizartinib as described through day 28 of cycle 2. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28). Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib, undergo repeat bone marrow aspiration/biopsy 1 week later, and proceed based on repeat aspiration/biopsy results as described. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28).
Upon completion of two cycles of therapy on either Arm A or Arm B, patients who are eligible can proceed to allogeneic stem cell transplant; while awaiting allogeneic stem cell transplant, patients should continue standard of care therapy.
Patients undergo echocardiography or MUGA scan during screening and undergo bone marrow aspiration and biopsy as well as blood sample collection throughout the study.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 5G2
- Recrutamento
- Arthur J E Child Comprehensive Cancer Centre
-
Contato:
- Site Public Contact
- Número de telefone: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Investigador principal:
- Mary L. Savoie
-
Edmonton, Alberta, Canadá, T6G 2B7
- Recrutamento
- University of Alberta Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Investigador principal:
- Joseph M. Brandwein
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 0V9
- Recrutamento
- CancerCare Manitoba
-
Contato:
- Site Public Contact
- Número de telefone: 866-561-1026
- E-mail: ctu_web@cancercare.mb.ca
-
Investigador principal:
- Brett L. Houston
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H 2Y9
- Recrutamento
- QEII Health Sciences Centre/Nova Scotia Health Authority
-
Contato:
- Site Public Contact
- Número de telefone: 902-473-6000
-
Investigador principal:
- Mahmoud Elsawy
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8V 5C2
- Recrutamento
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Contato:
- Site Public Contact
- Número de telefone: 905-387-9495
-
Investigador principal:
- Alejandro Garcia-Horton
-
Ottawa, Ontario, Canadá, K1H 8L6
- Recrutamento
- Ottawa Hospital and Cancer Center-General Campus
-
Contato:
- Site Public Contact
- Número de telefone: 613-761-4395
-
Investigador principal:
- Mitchell Sabloff
-
Toronto, Ontario, Canadá, M5G 2M9
- Suspenso
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Canadá, M4N 3M5
- Recrutamento
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
Contato:
- Site Public Contact
- Número de telefone: 416-480-5000
-
Investigador principal:
- Rena J. Buckstein
-
-
Quebec
-
Greenfield Park, Quebec, Canadá, J4V 2H1
- Recrutamento
- CSSS Champlain-Charles Le Moyne
-
Contato:
- Site Public Contact
- Número de telefone: 450-466-5065
-
Investigador principal:
- Sami Morin-Ben Abdallah
-
Montreal, Quebec, Canadá, H3T 1E2
- Recrutamento
- Jewish General Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 8248 514-340-8222
-
Investigador principal:
- Sarit E. Assouline
-
Montreal, Quebec, Canadá, H1T 2M4
- Recrutamento
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
Investigador principal:
- Julie Bergeron
-
Contato:
- Site Public Contact
- Número de telefone: 3329 514-252-3400
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Recrutamento
- University of Alabama at Birmingham Cancer Center
-
Investigador principal:
- Razan Mohty
-
Contato:
- Site Public Contact
- E-mail: gingerreeves@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Recrutamento
- Mayo Clinic Hospital in Arizona
-
Contato:
- Site Public Contact
- Número de telefone: 855-776-0015
-
Investigador principal:
- James M. Foran
-
Tucson, Arizona, Estados Unidos, 85719
- Recrutamento
- Banner University Medical Center - Tucson
-
Investigador principal:
- Sharad Khurana
-
Contato:
- Site Public Contact
- E-mail: UACC-IIT@uacc.arizona.edu
-
Tucson, Arizona, Estados Unidos, 85719
- Recrutamento
- University of Arizona Cancer Center-North Campus
-
Investigador principal:
- Sharad Khurana
-
Contato:
- Site Public Contact
- E-mail: UACC-IIT@uacc.arizona.edu
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Recrutamento
- University of Arkansas for Medical Sciences
-
Contato:
- Site Public Contact
- Número de telefone: 501-686-8274
-
Investigador principal:
- Ankur Varma
-
-
California
-
Berkeley, California, Estados Unidos, 94704
- Ativo, não recrutando
- Alta Bates Summit Medical Center-Herrick Campus
-
Dublin, California, Estados Unidos, 94568
- Recrutamento
- Kaiser Permanente Dublin
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
-
Investigador principal:
- Faisal N. Cheema
-
Fremont, California, Estados Unidos, 94538
- Recrutamento
- Kaiser Permanente-Fremont
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
Fresno, California, Estados Unidos, 93720
- Suspenso
- Kaiser Permanente-Fresno
-
Fresno, California, Estados Unidos, 93720
- Recrutamento
- Kaiser Permanente Fresno Orchard Plaza
-
Contato:
- Site Public Contact
- Número de telefone: 833-574-2273
-
Investigador principal:
- Faisal N. Cheema
-
Irvine, California, Estados Unidos, 92612
- Recrutamento
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Investigador principal:
- Deepa Jeyakumar
-
Contato:
- Site Public Contact
- Número de telefone: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Long Beach, California, Estados Unidos, 90822
- Ativo, não recrutando
- Tibor Rubin VA Medical Center
-
Los Angeles, California, Estados Unidos, 90048
- Recrutamento
- Cedars-Sinai Medical Center
-
Investigador principal:
- Noah M. Merin
-
Contato:
- Site Public Contact
- Número de telefone: 310-423-2133
- E-mail: Cancer.trial.info@cshs.org
-
Modesto, California, Estados Unidos, 95356
- Suspenso
- Kaiser Permanente-Modesto
-
Modesto, California, Estados Unidos, 95356
- Recrutamento
- Kaiser Permanente- Modesto MOB II
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
-
Investigador principal:
- Faisal N. Cheema
-
Oakland, California, Estados Unidos, 94611
- Recrutamento
- Kaiser Permanente-Oakland
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
Orange, California, Estados Unidos, 92868
- Recrutamento
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Investigador principal:
- Deepa Jeyakumar
-
Contato:
- Site Public Contact
- Número de telefone: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Roseville, California, Estados Unidos, 95661
- Recrutamento
- Kaiser Permanente-Roseville
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
Sacramento, California, Estados Unidos, 95817
- Recrutamento
- University of California Davis Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 916-734-3089
-
Investigador principal:
- Brian A. Jonas
-
Sacramento, California, Estados Unidos, 95814
- Recrutamento
- Kaiser Permanente Downtown Commons
-
Investigador principal:
- Faisal N. Cheema
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: kpoct@kp.org
-
Sacramento, California, Estados Unidos, 95823
- Recrutamento
- Kaiser Permanente-South Sacramento
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
San Francisco, California, Estados Unidos, 94115
- Recrutamento
- Kaiser Permanente-San Francisco
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
San Francisco, California, Estados Unidos, 94143
- Recrutamento
- UCSF Medical Center-Parnassus
-
Contato:
- Site Public Contact
- Número de telefone: 877-827-3222
-
Investigador principal:
- Timothy Ferng
-
San Jose, California, Estados Unidos, 95119
- Recrutamento
- Kaiser Permanente-Santa Teresa-San Jose
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
San Leandro, California, Estados Unidos, 94577
- Recrutamento
- Kaiser Permanente San Leandro
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
San Rafael, California, Estados Unidos, 94903
- Recrutamento
- Kaiser San Rafael-Gallinas
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
Santa Clara, California, Estados Unidos, 95051
- Recrutamento
- Kaiser Permanente Medical Center - Santa Clara
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
Santa Rosa, California, Estados Unidos, 95403
- Recrutamento
- Kaiser Permanente-Santa Rosa
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
South San Francisco, California, Estados Unidos, 94080
- Recrutamento
- Kaiser Permanente-South San Francisco
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
Vallejo, California, Estados Unidos, 94589
- Recrutamento
- Kaiser Permanente-Vallejo
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
Walnut Creek, California, Estados Unidos, 94596
- Recrutamento
- Kaiser Permanente-Walnut Creek
-
Contato:
- Site Public Contact
- Número de telefone: 877-642-4691
- E-mail: Kpoct@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Recrutamento
- Yale University
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Jan P. Bewersdorf
-
West Haven, Connecticut, Estados Unidos, 06516
- Recrutamento
- Veterans Affairs Connecticut Healthcare System-West Haven Campus
-
Contato:
- Site Public Contact
- Número de telefone: 2832 203-937-3421
-
Investigador principal:
- Alexander Pine
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610
- Recrutamento
- UF Health Cancer Institute - Gainesville
-
Contato:
- Site Public Contact
- Número de telefone: 352-273-8010
-
Investigador principal:
- Dina G. Khalaf
-
Jacksonville, Florida, Estados Unidos, 32224-9980
- Recrutamento
- Mayo Clinic in Florida
-
Contato:
- Site Public Contact
- Número de telefone: 855-776-0015
-
Investigador principal:
- James M. Foran
-
Miami, Florida, Estados Unidos, 33176
- Recrutamento
- Miami Cancer Institute
-
Investigador principal:
- Firas El Chaer
-
Contato:
- Site Public Contact
- Número de telefone: 786-596-2000
-
Pembroke Pines, Florida, Estados Unidos, 33028
- Recrutamento
- Memorial Hospital West
-
Contato:
- Site Public Contact
- Número de telefone: 954-265-4325
-
Investigador principal:
- Yehuda E. Deutsch
-
Ruskin, Florida, Estados Unidos, 33570
- Recrutamento
- Moffitt Cancer Center at SouthShore
-
Investigador principal:
- Rory M. Shallis
-
Contato:
- Site Public Contact
- Número de telefone: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Tampa, Florida, Estados Unidos, 33607
- Recrutamento
- Moffitt Cancer Center-International Plaza
-
Investigador principal:
- Rory M. Shallis
-
Contato:
- Site Public Contact
- Número de telefone: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Tampa, Florida, Estados Unidos, 33612
- Recrutamento
- Moffitt Cancer Center - McKinley Campus
-
Investigador principal:
- Rory M. Shallis
-
Contato:
- Site Public Contact
- Número de telefone: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Tampa, Florida, Estados Unidos, 33612
- Recrutamento
- Moffitt Cancer Center
-
Investigador principal:
- Rory M. Shallis
-
Contato:
- Site Public Contact
- Número de telefone: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Wesley Chapel, Florida, Estados Unidos, 33544
- Recrutamento
- Moffitt Cancer Center at Wesley Chapel
-
Investigador principal:
- Rory M. Shallis
-
Contato:
- Site Public Contact
- Número de telefone: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
-
Georgia
-
Albany, Georgia, Estados Unidos, 31701
- Recrutamento
- Phoebe Putney Memorial Hospital
-
Investigador principal:
- Vamsi Kota
-
Contato:
- Site Public Contact
- Número de telefone: 229-312-0405
- E-mail: ga_cares@augusta.edu
-
Augusta, Georgia, Estados Unidos, 30912
- Recrutamento
- Augusta University Medical Center
-
Investigador principal:
- Vamsi Kota
-
Contato:
- Site Public Contact
- Número de telefone: 706-721-2388
- E-mail: ga_cares@augusta.edu
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96826
- Recrutamento
- Kapiolani Medical Center for Women and Children
-
Investigador principal:
- Craig S. Boddy
-
Contato:
- Site Public Contact
- Número de telefone: 808-983-6090
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Investigador principal:
- Craig S. Boddy
-
Contato:
- Site Public Contact
- Número de telefone: 808-524-6115
- E-mail: i.webster@hawaiicancercare.com
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- Straub Clinic and Hospital
-
Investigador principal:
- Craig S. Boddy
-
Contato:
- Site Public Contact
- Número de telefone: 808-522-4333
-
Honolulu, Hawaii, Estados Unidos, 96819
- Recrutamento
- Kaiser Permanente Moanalua Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 808-432-5195
- E-mail: shelley.a.clark@kp.org
-
Investigador principal:
- Faisal N. Cheema
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Recrutamento
- Hawaii Cancer Care - Westridge
-
Investigador principal:
- Craig S. Boddy
-
Contato:
- Site Public Contact
- Número de telefone: 808-539-2273
- E-mail: info@hawaiicancercare.com
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Recrutamento
- Pali Momi Medical Center
-
Investigador principal:
- Craig S. Boddy
-
Contato:
- Site Public Contact
- Número de telefone: 808-486-6000
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83712
- Recrutamento
- Saint Luke's Cancer Institute - Boise
-
Contato:
- Site Public Contact
- Número de telefone: 208-381-2774
- E-mail: eslinget@slhs.org
-
Investigador principal:
- Charles W. Drescher
-
Boise, Idaho, Estados Unidos, 83706
- Recrutamento
- Saint Alphonsus Cancer Care Center-Boise
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-3671
- E-mail: stephanie.couch@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Caldwell, Idaho, Estados Unidos, 83605
- Recrutamento
- Saint Alphonsus Cancer Care Center-Caldwell
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-3671
- E-mail: stephanie.couch@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Recrutamento
- Kootenai Health - Coeur d'Alene
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Fruitland, Idaho, Estados Unidos, 83619
- Recrutamento
- Saint Luke's Cancer Institute - Fruitland
-
Contato:
- Site Public Contact
- Número de telefone: 208-381-2774
- E-mail: eslinget@slhs.org
-
Investigador principal:
- Charles W. Drescher
-
Meridian, Idaho, Estados Unidos, 83642
- Recrutamento
- Saint Luke's Cancer Institute - Meridian
-
Contato:
- Site Public Contact
- Número de telefone: 208-381-2774
- E-mail: eslinget@slhs.org
-
Investigador principal:
- Charles W. Drescher
-
Nampa, Idaho, Estados Unidos, 83687
- Recrutamento
- Saint Luke's Cancer Institute - Nampa
-
Contato:
- Site Public Contact
- Número de telefone: 208-381-2774
- E-mail: eslinget@slhs.org
-
Investigador principal:
- Charles W. Drescher
-
Nampa, Idaho, Estados Unidos, 83687
- Recrutamento
- Saint Alphonsus Cancer Care Center-Nampa
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Investigador principal:
- Tareq Al baghdadi
-
Post Falls, Idaho, Estados Unidos, 83854
- Recrutamento
- Kootenai Clinic Cancer Services - Post Falls
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Estados Unidos, 83864
- Recrutamento
- Kootenai Clinic Cancer Services - Sandpoint
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Illinois
-
Aurora, Illinois, Estados Unidos, 60506
- Recrutamento
- Advocate Outpatient Center - Aurora
-
Investigador principal:
- Thomas J. Saphner
-
Contato:
- Site Public Contact
- E-mail: ncorp@aah.org
-
Barrington, Illinois, Estados Unidos, 60010
- Recrutamento
- Advocate Good Shepherd Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-842-4847
-
Investigador principal:
- Thomas J. Saphner
-
Bloomington, Illinois, Estados Unidos, 61704
- Recrutamento
- Illinois CancerCare-Bloomington
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Bloomington, Illinois, Estados Unidos, 61701
- Recrutamento
- OSF Saint Joseph Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Canton, Illinois, Estados Unidos, 61520
- Recrutamento
- Illinois CancerCare-Canton
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Carthage, Illinois, Estados Unidos, 62321
- Recrutamento
- Illinois CancerCare-Carthage
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University of Chicago Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Investigador principal:
- Olatoyosi M. Odenike
-
Chicago, Illinois, Estados Unidos, 60611
- Recrutamento
- Northwestern University
-
Investigador principal:
- Jessica K. Altman
-
Contato:
- Site Public Contact
- Número de telefone: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Chicago, Illinois, Estados Unidos, 60612
- Recrutamento
- University of Illinois
-
Contato:
- Site Public Contact
- Número de telefone: 312-355-3046
-
Investigador principal:
- Noah Birch
-
Chicago, Illinois, Estados Unidos, 60657
- Recrutamento
- Advocate Illinois Masonic Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 773-296-5360
-
Investigador principal:
- Thomas J. Saphner
-
Chicago, Illinois, Estados Unidos, 60612
- Recrutamento
- Rush MD Anderson Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 312-226-2371
- E-mail: Cancer_Studies@rush.edu
-
Investigador principal:
- Melissa L. Larson
-
Crystal Lake, Illinois, Estados Unidos, 60014
- Recrutamento
- AMG Crystal Lake - Oncology
-
Contato:
- Site Public Contact
- Número de telefone: 630-929-6129
- E-mail: advocateresearch@advocate.com
-
Investigador principal:
- Thomas J. Saphner
-
Danville, Illinois, Estados Unidos, 61832
- Recrutamento
- Carle at The Riverfront
-
Investigador principal:
- Suparna Mantha
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@Carle.com
-
DeKalb, Illinois, Estados Unidos, 60115
- Recrutamento
- Northwestern Medicine Cancer Center Kishwaukee
-
Investigador principal:
- Jessica K. Altman
-
Contato:
- Site Public Contact
- Número de telefone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Decatur, Illinois, Estados Unidos, 62526
- Recrutamento
- Cancer Care Specialists of Illinois - Decatur
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Estados Unidos, 62526
- Recrutamento
- Decatur Memorial Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Dixon, Illinois, Estados Unidos, 61021
- Recrutamento
- Illinois CancerCare-Dixon
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 815-285-7800
-
Downers Grove, Illinois, Estados Unidos, 60515
- Recrutamento
- Advocate Good Samaritan Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 630-275-1270
- E-mail: Barbara.barhamand@advocatehealth.com
-
Investigador principal:
- Thomas J. Saphner
-
Effingham, Illinois, Estados Unidos, 62401
- Recrutamento
- Carle Physician Group-Effingham
-
Investigador principal:
- Suparna Mantha
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Effingham, Illinois, Estados Unidos, 62401
- Recrutamento
- Crossroads Cancer Center
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Estados Unidos, 60123
- Recrutamento
- Advocate Sherman Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-429-2907
-
Investigador principal:
- Thomas J. Saphner
-
Eureka, Illinois, Estados Unidos, 61530
- Recrutamento
- Illinois CancerCare-Eureka
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Evanston, Illinois, Estados Unidos, 60201
- Recrutamento
- NorthShore University HealthSystem-Evanston Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-570-2109
-
Investigador principal:
- Robert M. Eisner
-
Galesburg, Illinois, Estados Unidos, 61401
- Recrutamento
- Illinois CancerCare-Galesburg
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Geneva, Illinois, Estados Unidos, 60134
- Recrutamento
- Northwestern Medicine Cancer Center Delnor
-
Investigador principal:
- Jessica K. Altman
-
Contato:
- Site Public Contact
- Número de telefone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Glenview, Illinois, Estados Unidos, 60026
- Recrutamento
- NorthShore University HealthSystem-Glenbrook Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-570-2109
-
Investigador principal:
- Robert M. Eisner
-
Glenview, Illinois, Estados Unidos, 60026
- Recrutamento
- Northwestern Medicine Glenview Outpatient Center
-
Investigador principal:
- Jessica K. Altman
-
Contato:
- Site Public Contact
- Número de telefone: 312-695-1102
-
Grayslake, Illinois, Estados Unidos, 60030
- Recrutamento
- Northwestern Medicine Grayslake Outpatient Center
-
Investigador principal:
- Jessica K. Altman
-
Contato:
- Site Public Contact
- Número de telefone: 312-695-1102
-
Harvey, Illinois, Estados Unidos, 60426
- Recrutamento
- Ingalls Memorial Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 708-915-4673
- E-mail: clinicaltrials@ingalls.org
-
Investigador principal:
- Kimberly R. Kruczek
-
Hazel Crest, Illinois, Estados Unidos, 60429
- Recrutamento
- Advocate South Suburban Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 708-799-9995
-
Investigador principal:
- Thomas J. Saphner
-
Highland Park, Illinois, Estados Unidos, 60035
- Recrutamento
- NorthShore University HealthSystem-Highland Park Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-570-2109
-
Investigador principal:
- Robert M. Eisner
-
Hines, Illinois, Estados Unidos, 60141
- Recrutamento
- Edward Hines Jr VA Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 708-202-8387
-
Investigador principal:
- Jorgena Kosti-Schwartz
-
Kewanee, Illinois, Estados Unidos, 61443
- Recrutamento
- Illinois CancerCare-Kewanee Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Lake Forest, Illinois, Estados Unidos, 60045
- Recrutamento
- Northwestern Medicine Lake Forest Hospital
-
Investigador principal:
- Jessica K. Altman
-
Contato:
- Site Public Contact
- E-mail: cancertrials@northwestern.edu
-
Libertyville, Illinois, Estados Unidos, 60048
- Recrutamento
- AMG Libertyville - Oncology
-
Contato:
- Site Public Contact
- Número de telefone: 630-929-6129
- E-mail: advocateresearch@advocatehealth.com
-
Investigador principal:
- Thomas J. Saphner
-
Libertyville, Illinois, Estados Unidos, 60048
- Recrutamento
- Condell Memorial Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 630-929-6129
- E-mail: advocateresearch@advocatehealth.com
-
Investigador principal:
- Thomas J. Saphner
-
Macomb, Illinois, Estados Unidos, 61455
- Recrutamento
- Illinois CancerCare-Macomb
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Mattoon, Illinois, Estados Unidos, 61938
- Recrutamento
- Carle Physician Group-Mattoon/Charleston
-
Investigador principal:
- Suparna Mantha
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Maywood, Illinois, Estados Unidos, 60153
- Recrutamento
- Loyola University Medical Center
-
Investigador principal:
- Stephanie B. Tsai
-
Contato:
- Site Public Contact
- Número de telefone: 708-226-4357
-
O'Fallon, Illinois, Estados Unidos, 62269
- Recrutamento
- Cancer Care Center of O'Fallon
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Estados Unidos, 60453-2699
- Recrutamento
- Advocate Christ Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-323-8622
-
Investigador principal:
- Thomas J. Saphner
-
Oak Lawn, Illinois, Estados Unidos, 60453
- Recrutamento
- Advocate Outpatient Center - Oak Lawn
-
Investigador principal:
- Thomas J. Saphner
-
Contato:
- Site Public Contact
- E-mail: ncorp@aah.org
-
Orland Park, Illinois, Estados Unidos, 60462
- Recrutamento
- Northwestern Medicine Orland Park
-
Investigador principal:
- Jessica K. Altman
-
Contato:
- Site Public Contact
- E-mail: nctnprogram_rhlccc@northwestern.edu
-
Ottawa, Illinois, Estados Unidos, 61350
- Recrutamento
- Illinois CancerCare-Ottawa Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Palos Heights, Illinois, Estados Unidos, 60463
- Recrutamento
- Advocate High Tech Medical Park
-
Investigador principal:
- Thomas J. Saphner
-
Contato:
- Site Public Contact
- E-mail: ncorp@aah.org
-
Park Ridge, Illinois, Estados Unidos, 60068
- Recrutamento
- Advocate Lutheran General Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-384-3621
-
Investigador principal:
- Thomas J. Saphner
-
Pekin, Illinois, Estados Unidos, 61554
- Recrutamento
- Illinois CancerCare-Pekin
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Peoria, Illinois, Estados Unidos, 61615
- Recrutamento
- Illinois CancerCare-Peoria
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Peoria, Illinois, Estados Unidos, 61636
- Recrutamento
- Methodist Medical Center of Illinois
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Peoria, Illinois, Estados Unidos, 61637
- Recrutamento
- OSF Saint Francis Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Peru, Illinois, Estados Unidos, 61354
- Recrutamento
- Illinois CancerCare-Peru
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Princeton, Illinois, Estados Unidos, 61356
- Recrutamento
- Illinois CancerCare-Princeton
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
Springfield, Illinois, Estados Unidos, 62702
- Recrutamento
- Southern Illinois University School of Medicine
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-545-7929
-
Springfield, Illinois, Estados Unidos, 62702
- Recrutamento
- Springfield Clinic
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 800-444-7541
-
Springfield, Illinois, Estados Unidos, 62781
- Recrutamento
- Springfield Memorial Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-528-7541
- E-mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Estados Unidos, 61801
- Recrutamento
- Carle Cancer Center
-
Investigador principal:
- Suparna Mantha
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Warrenville, Illinois, Estados Unidos, 60555
- Recrutamento
- Northwestern Medicine Cancer Center Warrenville
-
Investigador principal:
- Jessica K. Altman
-
Contato:
- Site Public Contact
- Número de telefone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Washington, Illinois, Estados Unidos, 61571
- Recrutamento
- Illinois CancerCare - Washington
-
Contato:
- Site Public Contact
- Número de telefone: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Investigador principal:
- Bryan A. Faller
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Recrutamento
- Indiana University/Melvin and Bren Simon Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 317-278-5632
- E-mail: iutrials@iu.edu
-
Investigador principal:
- Rita Assi
-
-
Iowa
-
Ankeny, Iowa, Estados Unidos, 50023
- Recrutamento
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
Clive, Iowa, Estados Unidos, 50325
- Recrutamento
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Estados Unidos, 50314
- Recrutamento
- Mercy Medical Center - Des Moines
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Richard L. Deming
-
Des Moines, Iowa, Estados Unidos, 50309
- Recrutamento
- Iowa Methodist Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-6727
-
Investigador principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Estados Unidos, 50309
- Recrutamento
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Estados Unidos, 50314
- Recrutamento
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa/Holden Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-237-1225
-
Investigador principal:
- Prajwal Dhakal
-
Pella, Iowa, Estados Unidos, 50219
- Recrutamento
- UI Healthcare Mission Cancer and Blood - Pella
-
Investigador principal:
- Seema Harichand-Herdt
-
Contato:
- Site Public Contact
- Número de telefone: 515-282-2921
- E-mail: trials@missioncancer.com
-
Waukee, Iowa, Estados Unidos, 50263
- Recrutamento
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
West Des Moines, Iowa, Estados Unidos, 50266
- Recrutamento
- The Iowa Clinic PC
-
Investigador principal:
- Seema Harichand-Herdt
-
Contato:
- Site Public Contact
- Número de telefone: 515-875-9815
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- Recrutamento
- University of Kansas Clinical Research Center
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Tara L. Lin
-
Hays, Kansas, Estados Unidos, 67601
- Recrutamento
- HaysMed
-
Contato:
- Site Public Contact
- Número de telefone: 785-623-5774
-
Investigador principal:
- Tara L. Lin
-
Kansas City, Kansas, Estados Unidos, 66160
- Recrutamento
- University of Kansas Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Tara L. Lin
-
Lawrence, Kansas, Estados Unidos, 66044
- Recrutamento
- Lawrence Memorial Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 785-505-2800
- E-mail: Stephanie.Norris@LMH.ORG
-
Investigador principal:
- Tara L. Lin
-
Olathe, Kansas, Estados Unidos, 66061
- Recrutamento
- The University of Kansas Cancer Center - Olathe
-
Investigador principal:
- Tara L. Lin
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-1569
- E-mail: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Estados Unidos, 66211
- Recrutamento
- University of Kansas Hospital-Indian Creek Campus
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Tara L. Lin
-
Overland Park, Kansas, Estados Unidos, 66210
- Recrutamento
- University of Kansas Cancer Center-Overland Park
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Tara L. Lin
-
Salina, Kansas, Estados Unidos, 67401
- Recrutamento
- Salina Regional Health Center
-
Contato:
- Site Public Contact
- Número de telefone: 785-452-7038
- E-mail: mleepers@srhc.com
-
Investigador principal:
- Tara L. Lin
-
Topeka, Kansas, Estados Unidos, 66606
- Recrutamento
- University of Kansas Health System Saint Francis Campus
-
Contato:
- Site Public Contact
- Número de telefone: 785-295-8000
-
Investigador principal:
- Tara L. Lin
-
Topeka, Kansas, Estados Unidos, 66606
- Suspenso
- Cotton O'Neil Cancer Center / Stormont Vail Health
-
Westwood, Kansas, Estados Unidos, 66205
- Recrutamento
- University of Kansas Hospital-Westwood Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Tara L. Lin
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- Recrutamento
- University of Kentucky/Markey Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 859-257-3379
-
Investigador principal:
- Ayman Qasrawi
-
Louisville, Kentucky, Estados Unidos, 40202
- Recrutamento
- The James Graham Brown Cancer Center at University of Louisville
-
Investigador principal:
- Mohamed M. Hegazi
-
Contato:
- Site Public Contact
- Número de telefone: 502-562-3429
-
Louisville, Kentucky, Estados Unidos, 40245
- Recrutamento
- UofL Health Medical Center Northeast
-
Investigador principal:
- Mohamed M. Hegazi
-
Contato:
- Site Public Contact
- Número de telefone: 502-852-2755
- E-mail: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70805
- Recrutamento
- LSU Health Baton Rouge-North Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 225-765-7659
- E-mail: research@ololrmc.com
-
Investigador principal:
- Harry G. Sequeira Gross
-
Baton Rouge, Louisiana, Estados Unidos, 70808
- Recrutamento
- Our Lady of The Lake
-
Contato:
- Site Public Contact
- Número de telefone: 225-765-7659
-
Investigador principal:
- Harry G. Sequeira Gross
-
Baton Rouge, Louisiana, Estados Unidos, 70808
- Recrutamento
- Our Lady of the Lake Physician Group
-
Contato:
- Site Public Contact
- Número de telefone: 225-765-7659
- E-mail: research@ololrmc.com
-
Investigador principal:
- Harry G. Sequeira Gross
-
-
Maine
-
Brunswick, Maine, Estados Unidos, 04011
- Recrutamento
- Mid Coast Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Investigador principal:
- Pamela Egan
-
Brunswick, Maine, Estados Unidos, 04011
- Recrutamento
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Investigador principal:
- Pamela Egan
-
Contato:
- Site Public Contact
- Número de telefone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Portland, Maine, Estados Unidos, 04102
- Recrutamento
- MaineHealth Maine Medical Center - Portland
-
Investigador principal:
- Pamela Egan
-
Contato:
- Site Public Contact
- Número de telefone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Scarborough, Maine, Estados Unidos, 04074
- Recrutamento
- MaineHealth Maine Medical Center- Scarborough
-
Investigador principal:
- Pamela Egan
-
Contato:
- Site Public Contact
- Número de telefone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
South Portland, Maine, Estados Unidos, 04106
- Recrutamento
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Investigador principal:
- Pamela Egan
-
Contato:
- Site Public Contact
- Número de telefone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Recrutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Investigador principal:
- Alexander J. Ambinder
-
Bethesda, Maryland, Estados Unidos, 20889-5600
- Suspenso
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Dana-Farber Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 877-442-3324
-
Investigador principal:
- Richard M. Stone
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Beth Israel Deaconess Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 617-667-9925
-
Investigador principal:
- Malgorzata McMasters
-
Boston, Massachusetts, Estados Unidos, 02111
- Recrutamento
- Tufts Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 617-636-5000
- E-mail: ContactUsCancerCenter@TuftsMedicalCenter.org
-
Investigador principal:
- Andreas K. Klein
-
Worcester, Massachusetts, Estados Unidos, 01655
- Recrutamento
- UMass Memorial Medical Center - University Campus
-
Investigador principal:
- Jan Cerny
-
Contato:
- Site Public Contact
- Número de telefone: 508-856-3216
- E-mail: cancer.research@umassmed.edu
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Recrutamento
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Brighton, Michigan, Estados Unidos, 48114
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Canton, Michigan, Estados Unidos, 48188
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Chelsea, Michigan, Estados Unidos, 48118
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Clinton Township, Michigan, Estados Unidos, 48038
- Recrutamento
- Henry Ford Macomb Hospital-Clinton Township
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Ahmad H. Mattour
-
Detroit, Michigan, Estados Unidos, 48201
- Recrutamento
- Wayne State University/Karmanos Cancer Institute
-
Investigador principal:
- Vijendra Singh
-
Contato:
- Site Public Contact
- Número de telefone: 800-527-6266
- E-mail: ctoadmin@karmanos.org
-
Detroit, Michigan, Estados Unidos, 48202
- Recrutamento
- Henry Ford Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Ahmad H. Mattour
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Recrutamento
- Weisberg Cancer Treatment Center
-
Contato:
- Site Public Contact
- Número de telefone: 313-576-9790
- E-mail: ctoadmin@karmanos.org
-
Investigador principal:
- Vijendra Singh
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Genesys Hurley Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Tareq Al baghdadi
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Hurley Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Tareq Al baghdadi
-
Flint, Michigan, Estados Unidos, 48503
- Suspenso
- Genesee Hematology Oncology PC
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Cancer Hematology Centers - Flint
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Tareq Al baghdadi
-
Jackson, Michigan, Estados Unidos, 49201
- Recrutamento
- Allegiance Health
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Ahmad H. Mattour
-
Livonia, Michigan, Estados Unidos, 48154
- Recrutamento
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Novi, Michigan, Estados Unidos, 48377
- Recrutamento
- Henry Ford Medical Center-Columbus
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Ahmad H. Mattour
-
Pontiac, Michigan, Estados Unidos, 48341
- Recrutamento
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
West Bloomfield, Michigan, Estados Unidos, 48322
- Recrutamento
- Henry Ford West Bloomfield Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Ahmad H. Mattour
-
Ypsilanti, Michigan, Estados Unidos, 48197
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
-
Minnesota
-
Bemidji, Minnesota, Estados Unidos, 56601
- Recrutamento
- Sanford Joe Lueken Cancer Center
-
Investigador principal:
- Daniel Almquist
-
Contato:
- Site Public Contact
- Número de telefone: 218-333-5000
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Recrutamento
- Mercy Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Deer River, Minnesota, Estados Unidos, 56636
- Recrutamento
- Essentia Health - Deer River Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Investigador principal:
- Bret E. Friday
-
Duluth, Minnesota, Estados Unidos, 55805
- Recrutamento
- Essentia Health Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Investigador principal:
- Bret E. Friday
-
Edina, Minnesota, Estados Unidos, 55435
- Recrutamento
- Fairview Southdale Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Edina, Minnesota, Estados Unidos, 55435
- Recrutamento
- Minnesota Oncology - Edina
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Hibbing, Minnesota, Estados Unidos, 55746
- Recrutamento
- Essentia Health Hibbing Clinic
-
Investigador principal:
- Bret E. Friday
-
Contato:
- Site Public Contact
- Número de telefone: 218-786-3308
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Recrutamento
- Abbott-Northwestern Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Rochester, Minnesota, Estados Unidos, 55905
- Recrutamento
- Mayo Clinic in Rochester
-
Contato:
- Site Public Contact
- Número de telefone: 855-776-0015
-
Investigador principal:
- James M. Foran
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Recrutamento
- Park Nicollet Clinic - Saint Louis Park
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Recrutamento
- Regions Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Saint Paul, Minnesota, Estados Unidos, 55102
- Recrutamento
- United Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Virginia, Minnesota, Estados Unidos, 55792
- Recrutamento
- Essentia Health Virginia Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Investigador principal:
- Bret E. Friday
-
-
Mississippi
-
Columbus, Mississippi, Estados Unidos, 39705
- Recrutamento
- Baptist Memorial Hospital and Cancer Center-Golden Triangle
-
Investigador principal:
- Salil Goorha
-
Contato:
- Site Public Contact
- Número de telefone: 901-226-1366
- E-mail: BCCclintrials@bmhcc.org
-
Grenada, Mississippi, Estados Unidos, 38901
- Recrutamento
- Baptist Cancer Center-Grenada
-
Investigador principal:
- Salil Goorha
-
Contato:
- Site Public Contact
- Número de telefone: 901-226-1366
- E-mail: BCCclintrials@bmhcc.org
-
New Albany, Mississippi, Estados Unidos, 38652
- Recrutamento
- Baptist Memorial Hospital and Cancer Center-Union County
-
Investigador principal:
- Salil Goorha
-
Contato:
- Site Public Contact
- Número de telefone: 901-226-1366
- E-mail: BCCclintrials@bmhcc.org
-
Oxford, Mississippi, Estados Unidos, 38655
- Recrutamento
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Investigador principal:
- Salil Goorha
-
Contato:
- Site Public Contact
- Número de telefone: 901-226-1366
- E-mail: BCCclintrials@bmhcc.org
-
Southhaven, Mississippi, Estados Unidos, 38671
- Recrutamento
- Baptist Memorial Hospital and Cancer Center-Desoto
-
Investigador principal:
- Salil Goorha
-
Contato:
- Site Public Contact
- Número de telefone: 901-226-1366
- E-mail: BCCclintrials@bmhcc.org
-
-
Missouri
-
City of Saint Peters, Missouri, Estados Unidos, 63376
- Recrutamento
- Siteman Cancer Center at Saint Peters Hospital
-
Investigador principal:
- Geoffrey L. Uy
-
Contato:
- Site Public Contact
- Número de telefone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Recrutamento
- Siteman Cancer Center at West County Hospital
-
Investigador principal:
- Geoffrey L. Uy
-
Contato:
- Site Public Contact
- Número de telefone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Farmington, Missouri, Estados Unidos, 63640
- Recrutamento
- Parkland Health Center - Farmington
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 314-996-5569
-
Kansas City, Missouri, Estados Unidos, 64154
- Recrutamento
- University of Kansas Cancer Center - North
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Tara L. Lin
-
Kansas City, Missouri, Estados Unidos, 64108
- Recrutamento
- University Health Truman Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 816-404-4375
-
Investigador principal:
- Tara L. Lin
-
Kansas City, Missouri, Estados Unidos, 64116
- Recrutamento
- University of Kansas Cancer Center - Briarcliff
-
Investigador principal:
- Tara L. Lin
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
-
Lee's Summit, Missouri, Estados Unidos, 64064
- Recrutamento
- University of Kansas Cancer Center - Lee's Summit
-
Contato:
- Site Public Contact
- Número de telefone: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Investigador principal:
- Tara L. Lin
-
Saint Joseph, Missouri, Estados Unidos, 64506
- Suspenso
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Recrutamento
- Sainte Genevieve County Memorial Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 314-996-5569
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University School of Medicine
-
Investigador principal:
- Geoffrey L. Uy
-
Contato:
- Site Public Contact
- Número de telefone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
St Louis, Missouri, Estados Unidos, 63129
- Recrutamento
- Siteman Cancer Center-South County
-
Investigador principal:
- Geoffrey L. Uy
-
Contato:
- Site Public Contact
- Número de telefone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
St Louis, Missouri, Estados Unidos, 63136
- Recrutamento
- Siteman Cancer Center at Christian Hospital
-
Investigador principal:
- Geoffrey L. Uy
-
Contato:
- Site Public Contact
- Número de telefone: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
St Louis, Missouri, Estados Unidos, 63131
- Recrutamento
- Missouri Baptist Medical Center
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 314-996-5569
-
St Louis, Missouri, Estados Unidos, 63128
- Suspenso
- Mercy Hospital South
-
Sullivan, Missouri, Estados Unidos, 63080
- Recrutamento
- Missouri Baptist Sullivan Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Recrutamento
- Community Hospital of Anaconda
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Billings, Montana, Estados Unidos, 59101
- Recrutamento
- Billings Clinic Cancer Center
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 800-996-2663
- E-mail: research@billingsclinic.org
-
Bozeman, Montana, Estados Unidos, 59715
- Recrutamento
- Bozeman Health Deaconess Hospital
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Estados Unidos, 59405
- Recrutamento
- Benefis Sletten Cancer Institute
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Estados Unidos, 59901
- Recrutamento
- Logan Health Medical Center
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Missoula, Montana, Estados Unidos, 59802
- Recrutamento
- Saint Patrick Hospital - Community Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 406-327-3118
- E-mail: amy.hanneman@providence.org
-
Investigador principal:
- Charles W. Drescher
-
Missoula, Montana, Estados Unidos, 59804
- Recrutamento
- Community Medical Center
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Nebraska
-
Bellevue, Nebraska, Estados Unidos, 68123
- Recrutamento
- Nebraska Medicine-Bellevue
-
Contato:
- Site Public Contact
- Número de telefone: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Investigador principal:
- Michael Haddadin
-
Omaha, Nebraska, Estados Unidos, 68198
- Recrutamento
- University of Nebraska Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Investigador principal:
- Michael Haddadin
-
Omaha, Nebraska, Estados Unidos, 68118
- Recrutamento
- Nebraska Medicine-Village Pointe
-
Contato:
- Site Public Contact
- Número de telefone: 402-559-5600
-
Investigador principal:
- Michael Haddadin
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89102
- Suspenso
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Estados Unidos, 89183
- Suspenso
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Estados Unidos, 89502
- Suspenso
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Recrutamento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
Investigador principal:
- Raphael A. Lizcano
-
-
New Jersey
-
Basking Ridge, New Jersey, Estados Unidos, 07920
- Recrutamento
- Memorial Sloan Kettering Basking Ridge
-
Contato:
- Site Public Contact
- Número de telefone: 212-639-7592
-
Investigador principal:
- Aaron D. Goldberg
-
Camden, New Jersey, Estados Unidos, 08103
- Recrutamento
- Cooper Hospital University Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 856-325-6757
-
Investigador principal:
- Michael Brister
-
Livingston, New Jersey, Estados Unidos, 07039
- Recrutamento
- Cooperman Barnabas Medical Center
-
Investigador principal:
- Neil D. Palmisiano
-
Contato:
- Site Public Contact
- Número de telefone: 973-322-5200
-
Long Branch, New Jersey, Estados Unidos, 07740
- Recrutamento
- Monmouth Medical Center
-
Investigador principal:
- Neil D. Palmisiano
-
Contato:
- Site Public Contact
- Número de telefone: 732-923-6564
- E-mail: mary.danish@rwjbh.org
-
Middletown, New Jersey, Estados Unidos, 07748
- Recrutamento
- Memorial Sloan Kettering Monmouth
-
Contato:
- Site Public Contact
- Número de telefone: 212-639-7592
-
Investigador principal:
- Aaron D. Goldberg
-
Montvale, New Jersey, Estados Unidos, 07645
- Recrutamento
- Memorial Sloan Kettering Bergen
-
Contato:
- Site Public Contact
- Número de telefone: 212-639-7592
-
Investigador principal:
- Aaron D. Goldberg
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Recrutamento
- Rutgers Cancer Institute of New Jersey
-
Investigador principal:
- Neil D. Palmisiano
-
Contato:
- Site Public Contact
- Número de telefone: 732-235-7356
-
Paramus, New Jersey, Estados Unidos, 07652
- Recrutamento
- The Valley Hospital - Luckow Pavilion
-
Investigador principal:
- Jason Suh
-
Contato:
- Site Public Contact
- Número de telefone: 201-634-5792
- E-mail: clinicaltrialsresearch@valleyhealth.com
-
Ridgewood, New Jersey, Estados Unidos, 07450
- Recrutamento
- Valley Health System Ridgewood Campus
-
Investigador principal:
- Jason Suh
-
Contato:
- Site Public Contact
- Número de telefone: 201-634-5792
- E-mail: clinicaltrialsresearch@valleyhealth.com
-
Toms River, New Jersey, Estados Unidos, 08755
- Recrutamento
- Community Medical Center
-
Investigador principal:
- Neil D. Palmisiano
-
Contato:
- Site Public Contact
- Número de telefone: 732-557-8294
- E-mail: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- Recrutamento
- University of New Mexico Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 505-925-0348
- E-mail: HSC-ClinicalTrialInfo@salud.unm.edu
-
Investigador principal:
- Charles Foucar
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Recrutamento
- Roswell Park Cancer Institute
-
Investigador principal:
- Eunice S. Wang
-
Contato:
- Site Public Contact
- Número de telefone: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Commack, New York, Estados Unidos, 11725
- Recrutamento
- Memorial Sloan Kettering Commack
-
Contato:
- Site Public Contact
- Número de telefone: 212-639-7592
-
Investigador principal:
- Aaron D. Goldberg
-
Lake Success, New York, Estados Unidos, 11042
- Recrutamento
- Northwell Health/Center for Advanced Medicine
-
Contato:
- Site Public Contact
- Número de telefone: 516-734-8896
-
Investigador principal:
- David Chitty
-
Manhasset, New York, Estados Unidos, 11030
- Recrutamento
- North Shore University Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 516-734-8896
-
Investigador principal:
- David Chitty
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 212-639-7592
-
Investigador principal:
- Aaron D. Goldberg
-
New York, New York, Estados Unidos, 10029
- Recrutamento
- Mount Sinai Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 212-824-7309
- E-mail: CCTO@mssm.edu
-
Investigador principal:
- Douglas A. Tremblay
-
Rochester, New York, Estados Unidos, 14642
- Recrutamento
- University of Rochester
-
Contato:
- Site Public Contact
- Número de telefone: 585-275-5830
-
Investigador principal:
- Jane L. Liesveld
-
Rochester, New York, Estados Unidos, 14621
- Recrutamento
- Rochester General Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 585-922-3536
- E-mail: tia.derosa@rochestergeneral.org
-
Investigador principal:
- Maria M. Sbenghe
-
Stony Brook, New York, Estados Unidos, 11794
- Recrutamento
- Stony Brook University Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-862-2215
-
Investigador principal:
- Suhu Liu
-
Syracuse, New York, Estados Unidos, 13210
- Recrutamento
- State University of New York Upstate Medical University
-
Investigador principal:
- Teresa C. Gentile
-
Contato:
- Site Public Contact
- Número de telefone: 315-464-5476
-
The Bronx, New York, Estados Unidos, 10467
- Recrutamento
- Montefiore Medical Center - Moses Campus
-
Investigador principal:
- Ioannis Mantzaris
-
Contato:
- Site Public Contact
- Número de telefone: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Uniondale, New York, Estados Unidos, 11553
- Recrutamento
- Memorial Sloan Kettering Nassau
-
Contato:
- Site Public Contact
- Número de telefone: 212-639-7592
-
Investigador principal:
- Aaron D. Goldberg
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Recrutamento
- UNC Lineberger Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 877-668-0683
- E-mail: cancerclinicaltrials@med.unc.edu
-
Investigador principal:
- Lacey S. Williams
-
Charlotte, North Carolina, Estados Unidos, 28203
- Recrutamento
- Carolinas Medical Center/Levine Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
Investigador principal:
- Brittany K. Ragon
-
Charlotte, North Carolina, Estados Unidos, 28204
- Recrutamento
- Novant Health Presbyterian Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 980-201-6360
- E-mail: kashah@novanthealth.org
-
Investigador principal:
- Patricia L. Kropf
-
Durham, North Carolina, Estados Unidos, 27710
- Recrutamento
- Duke University Medical Center
-
Investigador principal:
- Harry P. Erba
-
Contato:
- Site Public Contact
- Número de telefone: 888-275-3853
-
Greenville, North Carolina, Estados Unidos, 27834
- Recrutamento
- East Carolina University
-
Investigador principal:
- Darla K. Liles
-
Contato:
- Site Public Contact
- Número de telefone: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Wilmington, North Carolina, Estados Unidos, 28401
- Recrutamento
- Novant Health New Hanover Regional Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 910-342-3000
-
Investigador principal:
- Swaleh A. Bahamadi
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Recrutamento
- Wake Forest University Health Sciences
-
Investigador principal:
- Matthew J. Wieduwilt
-
Contato:
- Site Public Contact
- Número de telefone: 336-713-6771
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Recrutamento
- Novant Health Forsyth Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 336-718-8335
- E-mail: pjordan@novanthealth.org
-
Investigador principal:
- James P. Dugan
-
-
North Dakota
-
Bismarck, North Dakota, Estados Unidos, 58501
- Recrutamento
- Sanford Bismarck Medical Center
-
Investigador principal:
- Daniel Almquist
-
Contato:
- Site Public Contact
- Número de telefone: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Estados Unidos, 58122
- Recrutamento
- Sanford Broadway Medical Center
-
Investigador principal:
- Daniel Almquist
-
Contato:
- Site Public Contact
- Número de telefone: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Estados Unidos, 58122
- Recrutamento
- Sanford Roger Maris Cancer Center
-
Investigador principal:
- Daniel Almquist
-
Contato:
- Site Public Contact
- Número de telefone: 701-234-6161
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Recrutamento
- Case Western Reserve University
-
Contato:
- Site Public Contact
- Número de telefone: 800-641-2422
- E-mail: CTUReferral@UHhospitals.org
-
Investigador principal:
- Benjamin K. Tomlinson
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- Ohio State University Comprehensive Cancer Center
-
Investigador principal:
- Alice S. Mims
-
Contato:
- Site Public Contact
- Número de telefone: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- University of Oklahoma Health Sciences Center
-
Contato:
- Site Public Contact
- Número de telefone: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Investigador principal:
- Manu Pandey
-
-
Oregon
-
Newberg, Oregon, Estados Unidos, 97132
- Recrutamento
- Providence Newberg Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Investigador principal:
- Charles W. Drescher
-
Ontario, Oregon, Estados Unidos, 97914
- Recrutamento
- Saint Alphonsus Cancer Care Center-Ontario
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Investigador principal:
- Tareq Al baghdadi
-
Oregon City, Oregon, Estados Unidos, 97045
- Recrutamento
- Providence Willamette Falls Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Investigador principal:
- Charles W. Drescher
-
Portland, Oregon, Estados Unidos, 97213
- Recrutamento
- Providence Portland Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Investigador principal:
- Charles W. Drescher
-
Portland, Oregon, Estados Unidos, 97225
- Recrutamento
- Providence Saint Vincent Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Investigador principal:
- Charles W. Drescher
-
Portland, Oregon, Estados Unidos, 97239
- Suspenso
- Oregon Health and Science University
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Recrutamento
- Lehigh Valley Hospital-Cedar Crest
-
Contato:
- Site Public Contact
- Número de telefone: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Investigador principal:
- Tareq Al baghdadi
-
Danville, Pennsylvania, Estados Unidos, 17822
- Recrutamento
- Geisinger Medical Center
-
Investigador principal:
- Joseph J. Vadakara
-
Contato:
- Site Public Contact
- Número de telefone: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Estados Unidos, 17033-0850
- Recrutamento
- Penn State Milton S Hershey Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 717-531-3779
- E-mail: CTO@hmc.psu.edu
-
Investigador principal:
- Joseph Cioccio
-
Lewistown, Pennsylvania, Estados Unidos, 17044
- Recrutamento
- Lewistown Hospital
-
Investigador principal:
- Joseph J. Vadakara
-
Contato:
- Site Public Contact
- Número de telefone: 717-242-7703
- E-mail: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Recrutamento
- Thomas Jefferson University Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 215-600-9151
- E-mail: ONCTrialNow@jefferson.edu
-
Investigador principal:
- Margaret T. Kasner
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- University of Pennsylvania/Abramson Cancer Center
-
Investigador principal:
- Keith W. Pratz
-
Contato:
- Site Public Contact
- Número de telefone: 215-349-8245
- E-mail: PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Recrutamento
- UPMC Hillman Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 412-647-8073
-
Investigador principal:
- Annie P. Im
-
West Reading, Pennsylvania, Estados Unidos, 19611
- Recrutamento
- Reading Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 610-988-9323
-
Investigador principal:
- Terrence P. Cescon
-
Wilkes-Barre, Pennsylvania, Estados Unidos, 18711
- Recrutamento
- Geisinger Wyoming Valley/Henry Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 570-271-5251
- E-mail: HemonCCTrials@geisinger.edu
-
Investigador principal:
- Joseph J. Vadakara
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Recrutamento
- Rhode Island Hospital
-
Investigador principal:
- John L. Reagan
-
Contato:
- Site Public Contact
- Número de telefone: 401-444-1488
-
-
South Carolina
-
Boiling Springs, South Carolina, Estados Unidos, 29316
- Recrutamento
- Prisma Health Cancer Institute - Spartanburg
-
Investigador principal:
- Suzanne R. Fanning
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Charleston, South Carolina, Estados Unidos, 29425
- Recrutamento
- Medical University of South Carolina
-
Investigador principal:
- Praneeth Baratam
-
Contato:
- Site Public Contact
- Número de telefone: 843-792-9321
- E-mail: hcc-clinical-trials@musc.edu
-
Easley, South Carolina, Estados Unidos, 29640
- Recrutamento
- Prisma Health Cancer Institute - Easley
-
Investigador principal:
- Suzanne R. Fanning
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Estados Unidos, 29605
- Recrutamento
- Prisma Health Cancer Institute - Faris
-
Investigador principal:
- Suzanne R. Fanning
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Estados Unidos, 29605
- Recrutamento
- Prisma Health Cancer Institute - Butternut
-
Investigador principal:
- Suzanne R. Fanning
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Estados Unidos, 29615
- Recrutamento
- Prisma Health Cancer Institute - Eastside
-
Investigador principal:
- Suzanne R. Fanning
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greer, South Carolina, Estados Unidos, 29650
- Recrutamento
- Prisma Health Cancer Institute - Greer
-
Investigador principal:
- Suzanne R. Fanning
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Seneca, South Carolina, Estados Unidos, 29672
- Recrutamento
- Prisma Health Cancer Institute - Seneca
-
Investigador principal:
- Suzanne R. Fanning
-
Contato:
- Site Public Contact
- Número de telefone: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Recrutamento
- Sanford Cancer Center Oncology Clinic
-
Investigador principal:
- Daniel Almquist
-
Contato:
- Site Public Contact
- Número de telefone: 605-312-3320
- E-mail: OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls, South Dakota, Estados Unidos, 57117-5134
- Recrutamento
- Sanford USD Medical Center - Sioux Falls
-
Investigador principal:
- Daniel Almquist
-
Contato:
- Site Public Contact
- Número de telefone: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Tennessee
-
Collierville, Tennessee, Estados Unidos, 38017
- Recrutamento
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Investigador principal:
- Salil Goorha
-
Contato:
- Site Public Contact
- Número de telefone: 901-226-1366
- E-mail: BCCclintrials@bmhcc.org
-
Knoxville, Tennessee, Estados Unidos, 37920
- Suspenso
- University of Tennessee - Knoxville
-
Memphis, Tennessee, Estados Unidos, 38120
- Recrutamento
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Investigador principal:
- Salil Goorha
-
Contato:
- Site Public Contact
- Número de telefone: 901-226-1366
- E-mail: BCCclintrials@bmhcc.org
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 713-798-1354
- E-mail: burton@bcm.edu
-
Investigador principal:
- Tareq Abuasab
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Ben Taub General Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 713-873-2000
-
Investigador principal:
- Tareq Abuasab
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Recrutamento
- Huntsman Cancer Institute/University of Utah
-
Contato:
- Site Public Contact
- Número de telefone: 888-424-2100
- E-mail: cancerinfo@hci.utah.edu
-
Investigador principal:
- Paul J. Shami
-
Salt Lake City, Utah, Estados Unidos, 84148
- Recrutamento
- George E Wahlen Department of Veterans Affairs Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 801-582-1565
-
Investigador principal:
- Tsewang Tashi
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05401
- Recrutamento
- University of Vermont Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 802-656-4101
- E-mail: rpo@uvm.edu
-
Investigador principal:
- Diego A. Adrianzen Herrera
-
Burlington, Vermont, Estados Unidos, 05405
- Recrutamento
- University of Vermont and State Agricultural College
-
Contato:
- Site Public Contact
- Número de telefone: 802-656-8990
- E-mail: rpo@uvm.edu
-
Investigador principal:
- Diego A. Adrianzen Herrera
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- Recrutamento
- University of Virginia Cancer Center
-
Investigador principal:
- Daniel R. Reed
-
Contato:
- Site Public Contact
- Número de telefone: 434-243-6303
- E-mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Fairfax, Virginia, Estados Unidos, 22031
- Recrutamento
- Inova Schar Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 703-720-5210
- E-mail: Stephanie.VanBebber@inova.org
-
Investigador principal:
- Danielle A. Shafer
-
Falls Church, Virginia, Estados Unidos, 22042
- Recrutamento
- Inova Fairfax Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 703-208-6650
- E-mail: Stephanie.VanBebber@inova.org
-
Investigador principal:
- Danielle A. Shafer
-
Richmond, Virginia, Estados Unidos, 23298
- Recrutamento
- VCU Massey Comprehensive Cancer Center
-
Investigador principal:
- Keri R. Maher
-
Contato:
- Site Public Contact
- Número de telefone: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Edmonds, Washington, Estados Unidos, 98026
- Recrutamento
- Swedish Cancer Institute-Edmonds
-
Investigador principal:
- Charles W. Drescher
-
Contato:
- Site Public Contact
- Número de telefone: 206-215-2343
- E-mail: PCRC-NCORP@Swedish.org
-
Issaquah, Washington, Estados Unidos, 98029
- Recrutamento
- Swedish Cancer Institute-Issaquah
-
Investigador principal:
- Charles W. Drescher
-
Contato:
- Site Public Contact
- Número de telefone: 206-215-2343
- E-mail: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Estados Unidos, 98122
- Recrutamento
- Swedish Medical Center-First Hill
-
Investigador principal:
- Charles W. Drescher
-
Contato:
- Site Public Contact
- Número de telefone: 206-215-2343
- E-mail: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Estados Unidos, 98195
- Recrutamento
- University of Washington Medical Center - Montlake
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-8824
-
Investigador principal:
- Jacob S. Appelbaum
-
Seattle, Washington, Estados Unidos, 98109
- Recrutamento
- Fred Hutchinson Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-8824
-
Investigador principal:
- Jacob S. Appelbaum
-
-
Wisconsin
-
Appleton, Wisconsin, Estados Unidos, 54911
- Recrutamento
- ThedaCare Regional Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 920-364-3604
- E-mail: ResearchDept@thedacare.org
-
Investigador principal:
- Yazhini Vallatharasu
-
Ashland, Wisconsin, Estados Unidos, 54806
- Recrutamento
- Duluth Clinic Ashland
-
Contato:
- Site Public Contact
- Número de telefone: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Investigador principal:
- Bret E. Friday
-
Burlington, Wisconsin, Estados Unidos, 53105
- Recrutamento
- Aurora Cancer Care-Southern Lakes VLCC
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Cudahy, Wisconsin, Estados Unidos, 53110
- Recrutamento
- Aurora Saint Luke's South Shore
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Recrutamento
- Marshfield Medical Center-EC Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Adedayo A. Onitilo
-
Germantown, Wisconsin, Estados Unidos, 53022
- Recrutamento
- Aurora Health Care Germantown Health Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Grafton, Wisconsin, Estados Unidos, 53024
- Recrutamento
- Aurora Cancer Care-Grafton
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Estados Unidos, 54311
- Recrutamento
- Aurora BayCare Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Estados Unidos, 54301
- Recrutamento
- Saint Vincent Hospital Cancer Center Green Bay
-
Investigador principal:
- Matthew L. Ryan
-
Contato:
- Site Public Contact
- Número de telefone: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Green Bay, Wisconsin, Estados Unidos, 54303
- Recrutamento
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Investigador principal:
- Matthew L. Ryan
-
Contato:
- Site Public Contact
- Número de telefone: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
Janesville, Wisconsin, Estados Unidos, 53548
- Recrutamento
- Mercyhealth Hospital and Cancer Center - Janesville
-
Contato:
- Site Public Contact
- Número de telefone: 608-756-6871
- E-mail: oncologyclinicaltrials@mhemail.org
-
Investigador principal:
- Emily G. Robinson
-
Kenosha, Wisconsin, Estados Unidos, 53142
- Recrutamento
- Aurora Cancer Care-Kenosha South
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Recrutamento
- Gundersen Lutheran Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 608-775-2385
- E-mail: cancerctr@gundersenhealth.org
-
Investigador principal:
- David E. Marinier
-
Madison, Wisconsin, Estados Unidos, 53705
- Recrutamento
- William S Middleton VA Medical Center
-
Investigador principal:
- Christopher D. Fletcher
-
Contato:
- Site Public Contact
- Número de telefone: 17007 608-256-1901
-
Madison, Wisconsin, Estados Unidos, 53792
- Recrutamento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Investigador principal:
- Kieran D. Sahasrabudhe
-
Contato:
- Site Public Contact
- Número de telefone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, Estados Unidos, 53718
- Recrutamento
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Investigador principal:
- Kieran D. Sahasrabudhe
-
Contato:
- Site Public Contact
- Número de telefone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Marinette, Wisconsin, Estados Unidos, 54143
- Recrutamento
- Aurora Bay Area Medical Group-Marinette
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Recrutamento
- Marshfield Medical Center-Marshfield
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Adedayo A. Onitilo
-
Menomonee Falls, Wisconsin, Estados Unidos, 53051
- Recrutamento
- Froedtert Menomonee Falls Hospital
-
Investigador principal:
- Ehab L. Atallah
-
Contato:
- Site Public Contact
- Número de telefone: 262-257-5100
-
Milwaukee, Wisconsin, Estados Unidos, 53209
- Recrutamento
- Aurora Cancer Care-Milwaukee
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Recrutamento
- Aurora Saint Luke's Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Medical College of Wisconsin
-
Investigador principal:
- Ehab L. Atallah
-
Contato:
- Site Public Contact
- Número de telefone: 414-805-3666
-
Milwaukee, Wisconsin, Estados Unidos, 53233
- Recrutamento
- Aurora Sinai Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Recrutamento
- Marshfield Medical Center - Minocqua
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Adedayo A. Onitilo
-
Mukwonago, Wisconsin, Estados Unidos, 53149
- Recrutamento
- ProHealth D N Greenwald Center
-
Contato:
- Site Public Contact
- E-mail: research.institute@phci.org
-
Investigador principal:
- Timothy R. Wassenaar
-
New Berlin, Wisconsin, Estados Unidos, 53151
- Recrutamento
- Froedtert and MCW Moorland Reserve Health Center
-
Investigador principal:
- Ehab L. Atallah
-
Contato:
- Site Public Contact
- Número de telefone: 414-805-0505
-
Oak Creek, Wisconsin, Estados Unidos, 53154
- Recrutamento
- Drexel Town Square Health Center
-
Investigador principal:
- Ehab L. Atallah
-
Contato:
- Site Public Contact
- Número de telefone: 414-805-0505
-
Oconomowoc, Wisconsin, Estados Unidos, 53066
- Recrutamento
- ProHealth Oconomowoc Memorial Hospital
-
Investigador principal:
- Timothy R. Wassenaar
-
Contato:
- Site Public Contact
- Número de telefone: 262-928-7878
-
Oconto Falls, Wisconsin, Estados Unidos, 54154
- Recrutamento
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Investigador principal:
- Matthew L. Ryan
-
Contato:
- Site Public Contact
- Número de telefone: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Recrutamento
- Vince Lombardi Cancer Clinic - Oshkosh
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Racine, Wisconsin, Estados Unidos, 53406
- Recrutamento
- Aurora Cancer Care-Racine
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Recrutamento
- Marshfield Medical Center-Rice Lake
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Adedayo A. Onitilo
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Recrutamento
- Vince Lombardi Cancer Clinic-Sheboygan
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Recrutamento
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Investigador principal:
- Matthew L. Ryan
-
Contato:
- Site Public Contact
- Número de telefone: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Recrutamento
- Marshfield Medical Center-River Region at Stevens Point
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Adedayo A. Onitilo
-
Sturgeon Bay, Wisconsin, Estados Unidos, 54235-1495
- Recrutamento
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Investigador principal:
- Matthew L. Ryan
-
Contato:
- Site Public Contact
- Número de telefone: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
Summit, Wisconsin, Estados Unidos, 53066
- Recrutamento
- Aurora Medical Center in Summit
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Two Rivers, Wisconsin, Estados Unidos, 54241
- Recrutamento
- Vince Lombardi Cancer Clinic-Two Rivers
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Recrutamento
- ProHealth Waukesha Memorial Hospital
-
Investigador principal:
- Timothy R. Wassenaar
-
Contato:
- Site Public Contact
- Número de telefone: 262-928-7632
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Recrutamento
- UW Cancer Center at ProHealth Care
-
Investigador principal:
- Timothy R. Wassenaar
-
Contato:
- Site Public Contact
- Número de telefone: 262-928-5539
- E-mail: Chanda.miller@phci.org
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Aurora Cancer Care-Milwaukee West
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
West Allis, Wisconsin, Estados Unidos, 53227
- Recrutamento
- Aurora West Allis Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
West Bend, Wisconsin, Estados Unidos, 53095
- Recrutamento
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Investigador principal:
- Ehab L. Atallah
-
Contato:
- Site Public Contact
- Número de telefone: 414-805-0505
-
Weston, Wisconsin, Estados Unidos, 54476
- Recrutamento
- Marshfield Medical Center - Weston
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Adedayo A. Onitilo
-
-
-
-
-
San Juan, Porto Rico, 00927
- Recrutamento
- Centro Comprensivo de Cancer de UPR
-
Investigador principal:
- Luis J. Santos Reyes
-
Contato:
- Site Public Contact
- Número de telefone: 888-823-5923
- E-mail: ctsucontact@westat.com
-
San Juan, Porto Rico, 00936
- Recrutamento
- San Juan City Hospital
-
Investigador principal:
- Luis J. Santos Reyes
-
Contato:
- Site Public Contact
- Número de telefone: 787-763-1296
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS.
-
Participants must be >= 18 years of age.
-
Participants must not have received prior anti-cancer therapy for AML or MDS.
- Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
- Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m^2 of cytarabine, which is allowed for urgent cytoreduction.
-
Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure.
- Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment.
-
Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy
- Note: active hormonal therapy is allowed
-
Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration.
-
Participants must agree to have translational medicine specimens submitted.
-
Participants must be offered the opportunity to participate in specimen banking.
- Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.
- Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Triagem
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: MM1MDS-A01 Regimen 1 (ASTX727)
Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)
Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Experimental: MM1MDS-CTG02 Arm 1 (Luspatercept)
Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given SC
Outros nomes:
|
|
Experimental: MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)
Patients receive luspatercept SC on day 1 and epoetin alfa SC QW for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Given SC
Outros nomes:
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given SC
Outros nomes:
|
|
Experimental: MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)
Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given SC
Outros nomes:
Given PO
Outros nomes:
|
|
Experimental: MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Outros nomes:
Given PO
Outros nomes:
Given IV or SC
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Outros nomes:
Given PO
Outros nomes:
Given IV or SC
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Experimental: MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Outros nomes:
Given PO
Outros nomes:
Given IV or SC
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Comparador Ativo: MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)
Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)
Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Experimental: MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)
Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Comparador Ativo: MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)
Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1OA-MDS-A05 Cohort C (olutasidenib)
Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Comparador Ativo: MM1OA-S03 Arm 1 (ASTX727, venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial. |
Undergo bone marrow biopsy
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Comparador Ativo: MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Given PO
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Given PO
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Comparador Ativo: MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)
Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study. |
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given IV
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Receive SOC treatment
Outros nomes:
|
|
Experimental: MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)
Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study. |
Given IV
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given IV
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Receive SOC treatment
Outros nomes:
|
|
Experimental: MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)
Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Given IV
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given IV
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1YA-CTG01 Arm II (azacitidine, venetoclax)
Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Given IV or SC
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Comparador Ativo: MM1YA-CTG01 Arm III (daunorubicin, cytarabine)
Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Given IV
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given IV
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)
See Detailed Description. |
Given IV
Outros nomes:
Undergo bone marrow biopsy
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given IV
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Experimental: MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)
See Detailed Description. |
Undergo bone marrow biopsy
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Given IV or SC
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given PO
Outros nomes:
|
|
Comparador Ativo: MM1YA-S01 Arm I (cytarabine, daunorubicin)
Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Given IV
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given IV
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Given IV
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given IV
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1YA-S01 Arm III (azacitidine, venetoclax)
Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Given IV or SC
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1YA-S01 Arm IV (Vyxeos)
Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given IV
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: MM1YA-S01 Arm V (Vyxeos, venetoclax)
Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo bone marrow aspiration Given PO
Outros nomes:
Given IV
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Comparador Ativo: MM2YA-EA01 Arm A (cytarabine)
Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Given IV
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo biopsy
Outros nomes:
|
|
Experimental: MM2YA-EA01 Arm B (cytarabine, venetoclax)
Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Given IV
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo biopsy
Outros nomes:
Given PO
Outros nomes:
|
|
Experimental: MM2YA-EA01 Arm C (Vyxeos, venetoclax)
Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo biopsy
Outros nomes:
Given PO
Outros nomes:
Given IV
Outros nomes:
|
|
Experimental: MM2YA-EA01 Arm D (azacitidine, venetoclax)
Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo biopsy
Outros nomes:
Given PO
Outros nomes:
Given IV or SC
Outros nomes:
|
|
Experimental: MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)
Patients receive venetoclax PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Undergo CT
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo PET
Outros nomes:
Given IV
Outros nomes:
Given PO
Outros nomes:
Given IV
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given IV
Outros nomes:
Undergo chest x-ray
Outros nomes:
Given IV
Outros nomes:
|
|
Comparador de Placebo: MM3TCT-A03 Conditioning 1B (matched donors with placebo)
Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Undergo CT
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo PET
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given IV
Outros nomes:
Undergo chest x-ray
Outros nomes:
Given IV
Outros nomes:
|
|
Experimental: MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)
Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Undergo CT
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo PET
Outros nomes:
Given PO
Outros nomes:
Given IV
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given IV
Outros nomes:
Undergo chest x-ray
Outros nomes:
Given IV
Outros nomes:
Undergo total body irradiation
Outros nomes:
|
|
Comparador de Placebo: MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)
Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Undergo CT
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo PET
Outros nomes:
Given IV
Outros nomes:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
Given IV
Outros nomes:
Undergo chest x-ray
Outros nomes:
Given IV
Outros nomes:
Undergo total body irradiation
Outros nomes:
|
|
Experimental: MM3TCT-A03 Maintenance I (venetoclax)
Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Undergo CT
Outros nomes:
Undergo MUGA
Outros nomes:
Undergo PET
Outros nomes:
Given PO
Outros nomes:
Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Comparador de Placebo: MM3TCT-A03 Maintenance II (placebo)
Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Outros nomes:
Undergo CT
Outros nomes:
Undergo PET
Outros nomes:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Outros nomes:
|
|
Experimental: Screening (mutation carrier screening)
Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP. |
Undergo rapid genetic testing |
|
Experimental: TAP (SOC treatment, mutation carrier screening)
Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment. |
Receive SOC treatment
Outros nomes:
Undergo rapid genetic testing |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will evaluate the feasibility of MATCHBox generating all data needed for assignment to a myeloMATCH clinical trial or determination that no assignment is available, within 72 hours of MDNet receipt of specimens for initial therapy and within 10 days for subsequent therapy. For first treatment assignment and separately for each subsequent treatment assignments: every 50 participants for the first 250 participants and then every 100 participants thereafter, the proportion of participants (cumulative and new participants since prior analysis) with all MDNet data needed to determine a treatment assignment within 72 hours for first assignment and 10 days for subsequent assignments after the MDNet receives specimens will be tallied. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to MDNet generating all data required for treatment substudy or TAP assignment
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Time to treatment substudy or TAP assignment
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Percent assigned to a myeloMATCH clinical trial
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Percent of screened participants who register to a treatment substudy
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Assignment to higher tier treatment substudies within myeloMATCH
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Adverse events
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Minimal residual disease (MRD) response
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
MRD response is based on flow cytometry studies performed by the MDnet. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Time-to-event outcomes for exploratory analysis
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Performance status
Prazo: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Participants will be graded according to the Zubrod performance status scale. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jerald P Radich, SWOG Cancer Research Network
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Leucemia Mieloide
- Doenças da Medula Óssea
- Leucemia
- Doenças hemic e linfáticas
- Leucemia Mieloide Aguda
- Síndromes Mielodisplásicas
- Distúrbios mieloproliferativos
- Administração de Serviços de Saúde
- Qualidade, acesso e avaliação da assistência médica
- Peptídeos
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Preparações farmacêuticas
- Técnicas de investigação
- Terapêutica
- Formas de dose
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Procedimentos cirúrgicos, operatórios
- Rotas de administração de medicamentos
- Terapia medicamentosa
- Técnicas citológicas
- Ácidos nucleicos, nucleotídeos e nucleosídeos
- Citodiagnóstico
- Hidrocarbonetos, acíclico
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Fatores biológicos
- Qualidade de assistência médica
- Carboidratos
- Fenômenos físicos
- Hidrocarbonetos aromáticos policíclicos
- Hidrocarbonetos, aromáticos
- Compostos policíclicos
- Glicosídeos
- Indicadores de qualidade, assistência médica
- Transplantação
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Aminoácidos
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Alcans
- Técnicas de diagnóstico, cirúrgico
- Materiais biomédicos e dentários
- Materiais fabricados
- Tecnologia, indústria e agricultura
- Álcoons
- Técnicas de química, analíticas
- Butileno glicols
- Glicols
- Mesilatos
- Alkanesulfonatos
- Ácidos alcanesulfônicos
- Ácidos sulfônicos
- Ácidos de enxofre
- Análise de espectro
- Compostos de mostarda de nitrogênio
- Compostos de mostarda
- Hidrocarbonetos, halogenados
- Compostos AZA
- Nucleosídeos
- Ribonucleosídeos
- Peptídeos e proteínas de sinalização intercelular
- Arabinonucleosides
- Antraciclinas
- Nafthacenos
- Aminoglicosídeos
- Glicoproteínas
- Glicoconjugados
- Fenômenos eletromagnéticos
- Fenômenos magnéticos
- Radioterapia
- Transplante de células
- Terapia baseada em células e tecidos
- Terapia biológica
- Fenilalanina
- Aminoácidos, aromáticos
- Aminoácidos, cíclicos
- Radiação eletromagnética
- Radiação
- Radiação, ionizando
- Diretrizes como tópico
- Garantia de qualidade, assistência médica
- Fatores estimuladores de colônias
- Fatores de crescimento celular hematopoiético
- Citocinas
- Calicheamicins
- Membranas, artificiais
- Portadores de drogas
- Materiais biomiméticos
- Eritropoietina
- Epoetina Alfa
- Gentuzumabe
- Citarabina
- Melfalano
- Azacitidina
- Daunorrubicina
- Bussulfano
- Injeções
- Padrão de atendimento
- Biópsia
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- fludarabina
- Venetoclax
- Transplante de células -tronco
- combinação de drogas decitabina e cedazuridina
- Raios X
- Diretrizes de prática como tópico
- Irradiação de corpo inteiro
- enasidenib
- Quizartinibe
- Gilteritinib
- CPX-351
- Lipossomas
- CA-4948
- Olutasidenib
- luspatercept
Outros números de identificação do estudo
- NCI-2022-07006
- U10CA180888 (Concessão/Contrato do NIH dos EUA)
- NCI-2022-07006 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- MYELOMATCH (Outro identificador: CTEP)
- MYELOMATCH (Outro identificador: SWOG)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .